Abstract
Despite their different histological and molecular properties, different types of cancers share few essential functional alterations. Some of these cancer hallmarks may easily be studied in in vitro cultures, while others are related to the way in which tumors grow in vivo.
According to the systems biology paradigm, complex cellular functions arise as system-level properties from the dynamic interaction of a large number of biomolecules. We previously newly defined four basic cancer cell properties derived from known cancer hallmarks amenable to system-level investigation in cell cultures: enhanced growth, altered response to apoptotic cues, genomic instability and inability to enter senescence following oncogenic signaling.
Here we summarize the major properties of enhanced growth that is dependent on metabolism rewiring - in which glucose is mostly used by fermentation while glutamine provides nitrogen and carbon atoms for biosyntheses – and controlled by oncogene signaling. We then briefly review the major drugs used to target signaling pathways in preclinical and clinical studies, whose clinical efficacy is unfortunately severely limited by tumor resistance, substantially due to signaling cross-talk.
We present a systems biology roadmap that integrates different types of mathematical models with conventional and post-genomic biomolecular analyses that will provide a deeper mechanistic understanding of the links between metabolism and uncontrolled cancer cell growth. This approach is taken to be instrumental both in unraveling cancer’s first principles and in designing novel drugs able to target one or more control or execution steps of the cancer rewired metabolism, in order to achieve permanent arrest of tumor development.
Keywords: Model, metabolic rewiring, glutamine, Warburg effect.
Current Pharmaceutical Design
Title:A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Volume: 20 Issue: 15
Author(s): Lilia Alberghina, Daniela Gaglio, Rosa Maria Moresco, Maria Carla Gilardi, Cristina Messa and Marco Vanoni
Affiliation:
Keywords: Model, metabolic rewiring, glutamine, Warburg effect.
Abstract: Despite their different histological and molecular properties, different types of cancers share few essential functional alterations. Some of these cancer hallmarks may easily be studied in in vitro cultures, while others are related to the way in which tumors grow in vivo.
According to the systems biology paradigm, complex cellular functions arise as system-level properties from the dynamic interaction of a large number of biomolecules. We previously newly defined four basic cancer cell properties derived from known cancer hallmarks amenable to system-level investigation in cell cultures: enhanced growth, altered response to apoptotic cues, genomic instability and inability to enter senescence following oncogenic signaling.
Here we summarize the major properties of enhanced growth that is dependent on metabolism rewiring - in which glucose is mostly used by fermentation while glutamine provides nitrogen and carbon atoms for biosyntheses – and controlled by oncogene signaling. We then briefly review the major drugs used to target signaling pathways in preclinical and clinical studies, whose clinical efficacy is unfortunately severely limited by tumor resistance, substantially due to signaling cross-talk.
We present a systems biology roadmap that integrates different types of mathematical models with conventional and post-genomic biomolecular analyses that will provide a deeper mechanistic understanding of the links between metabolism and uncontrolled cancer cell growth. This approach is taken to be instrumental both in unraveling cancer’s first principles and in designing novel drugs able to target one or more control or execution steps of the cancer rewired metabolism, in order to achieve permanent arrest of tumor development.
Export Options
About this article
Cite this article as:
Alberghina Lilia, Gaglio Daniela, Moresco Maria Rosa, Gilardi Carla Maria, Messa Cristina and Vanoni Marco, A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990490
DOI https://dx.doi.org/10.2174/13816128113199990490 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders
Current Topics in Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Biomarkers of Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), A Review of Published Patents and Patent Applications
Recent Patents on Biomarkers Molecular Dynamics Simulations, Challenges and Opportunities: A Biologist’s Prospective
Current Protein & Peptide Science Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets The Pharmacogenetics of Asthma Therapy
Current Drug Targets Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Effects of Opiates and HIV Proteins on Neurons: The Role of Ferritin Heavy Chain and a Potential for Synergism
Current HIV Research Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design